lagen and Matrigel, the researchers found that medicalgrade bovine collagen works equally well. In addition, to optimize cell viability, cardiomyocyte size, nonmyocyte cell size, cardiomyocyte and nonmyocyte percentage, or enhanced cardiomyocyte α-actinin content, a factorial screening was performed. insulin-like growth factor 1, fibroblast growth factor 2, vascular endothelial growth factor 165, and transforming growth factor beta 1 were chosen because this combination of growth factors leads to (1) neutral or enhanced cell viability, and (2) enhanced cardiomyocyte actinin content or cardiomyocyte size. Another important note from the article is that the authors pointed out that the commonly used cardiomyocyte medium, Roswell Park Memorial Institute medium, only contains 0.42 mmol/L of calcium, which is one-third of the physiological level (1.2 mmol/L). When we consider the essential role of calcium for cardiac development and function, we feel an urgent need for the cardiovascular community to realize this and appropriately adjust the Roswell Park Memorial Institute medium.
The maturation status of the cardiomyocytes in the EHM goes significantly beyond the state of the art in several respects. First, the human cardiac constructs displayed a positive force-frequency relationship, which is absent in human newborns but develops over the first year of life. 10 The positive force-frequency relationship is a complex trait that relates to increased calcium loading of the sarcoplasmic reticulum with increasing stimulation frequency. Multiple components of excitation-contraction coupling must be integrated for this phenomenon, including an increased calcium influx by the L-type calcium channel, increased levels of sarcoendoplasmic reticulum calcium ATPase, increased phospholamban, and potentially reduced Na/Ca exchange. Although our group had recently matured engineered human heart muscle to the point where the force-frequency relationship went from negative to flat, 11 to our knowledge, this is the first demonstration of a positive force-frequency relationship in engineered human myocardium.
Second, the authors observed both inotropic and lusitropic responses of the cardiac constructs to β-adrenergic stimulation, suggesting an upregulation of phospholamban, the calcium handling regulatory protein targeted by β-adrenergic stimulation. This may be the first report of both an inotropic and a lusitropic response to β-adrenergic stimulation in hPSC-CM, although Bursac's group had previously demonstrated a positive inotropic effect. 12 Third, the cardiomyocytes isolated from EHM are rodshaped, and, impressively, electron microscopy reveals M-bands. In electron micrographs of the sarcomere, the M-band appears as a series of parallel electron-dense lines in the central zone of the A-band. The M-band has been reported to play a role in mechanical stability in the activated sarcomere, as well as the biomechanical conditions in contracting muscle such as stress sensing. During human heart development, M-bands develop postnatally. Before this article, only 1 other article showed the appearance of M-bands in the minority of 360-day-old embryoid body-derived cardiomyocytes. 13 Finally, the contractile force generated by EHM amounted to 6.2 mN/mm 2 after 8 weeks in culture, and this exceeded the force by papillary muscle from 3-to 14-month human infants significantly. 10 Although this EHM force improved by ≈5 times during optimization, it is short of the 23.2 mN/mm 2 achieved in EHMs built by Jackman et al, 14 so other conditions remain to be optimized.
Where do we go from here? Obviously, room for improvement still exists. The overall degree of cardiac maturation, although better than previously reported and observed in standard 2D cultures, is still limited and needs to be further improved. The force generated by the EHM is ≈6.2 mN/mm 2 , which is about one-fourth of a normal adult heart muscle. Individual cardiomyocyte volume is less than one-third of their counterparts in the adult human heart mainly because of a significantly smaller cell width. In addition, unbiased global transcriptome profiling suggested that EHM is largely similar to the human fetal heart at 13 weeks of gestation. It is worth further investigating to assess whether combining multiple cues, eg, enhancing EHM preload and afterload, electric stimulation, growth hormonal treatment, or microRNA will lead to greater degree of EHM maturation.
Are the EHMs useful in their current state? With a record level of hPSC-CM maturation, one could reason that the EHM serves as a better model for drug screening and disease modeling. Tiburcy et al 8 provide evidence for this in their article. EHM responded to chronic catecholamine toxicity with some of the classical hallmarks of heart failure, including contractile dysfunction, cardiomyocyte hypertrophy, cardiomyocyte death, and NT-proBNP (N-Terminal pro-B-Type Natriuretic Peptide) release.
Could the EHM be used for heart regeneration? In the article, the authors scaled up the EHM patch production, reaching sizes relative to clinical translation and transplanted the EHM patches into normal nude rats through epicardial delivery. Grafts were detected 107 days after implantation, and encouragingly, the grafts were vascularized. However, it was not investigated whether the grafts are electromechanically coupled with the host rat hearts. Actually, histology showed a substantial gap (probably fibrous tissue) between grafts and host hearts. 8 This finding indicates that the grafts may not contract in synchrony with the host hearts. Indeed, by ex vivo fluorescent imaging of hPSC-derived cardiomyocytes expressing GCaMP3 calcium reporter, our group has shown that after implantation on the epicardial surface, cardiomyocytes in scaffold-free tissue patches were electromechanically active but beat slowly and were not electrically coupled to the host infarcted hearts. 15 Histologically, scar tissue physically separated the patch graft and host myocardium. Therefore, additional studies will be required to promote electric and mechanical integration of epicardially implanted engineered tissues, which continues to be a promising approach.
In conclusion, the present study by Tiburcy and colleagues 8 is a nice piece of work that advances the field of cardiac tissue engineering by establishing a defined protocol to generate and culture functional human heart muscles from pluripotent stem cells. Many questions, including those formulated earlier, need to be answered, but this current study made significant strides in standardizing the production and maturation of engineered human myocardium.
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